Sporanox (itraconazole): Reviews and patient testimonials

Sporanox 10 mg/ml Oral Solution

SPORANOX Oral Solution is indicated:

- for the treatment of oral and/or oesophageal candidosis in HIV-positive or other immunocompromised patients.

- as prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole, when standard therapy is considered inappropriate, in patients with haematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (i.e. < 500 cells/µl). At present, there are insufficient clinical efficacy data in the prevention of aspergillosis.

Consideration should be given to national and/or local guidance regarding the appropriate use of antifungal agents.

Sporanox Capsules

1. Vulvovaginal candidosis.

2. Pityriasis versicolor.

3. Dermatophytoses caused by organisms susceptible to itraconazole (Trichophyton spp., Microsporum spp., Epidermophyton floccosum) e.g. tinea pedis, tinea cruris, tinea corporis, tinea manuum.

4. Oropharyngeal candidosis.

5. Onychomycosis caused by dermatophytes and/or yeasts.

6. The treatment of histoplasmosis.

7. Sporanox is indicated in the following systemic fungal conditions when first-line systemic anti-fungal therapy is inappropriate or has proved ineffective. This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.

	- Treatment of aspergillosis and candidosis
	- Treatment of cryptococcosis (including cryptococcal meningitis): in immunocompromised patients with cryptococcosis and in all patients with cryptococcosis of the central nervous system.
	- Maintenance therapy in AIDS patients to prevent relapse of underlying fungal infection.

Sporanox is also indicated in the prevention of fungal infection during prolonged neutropenia when standard therapy is considered inappropriate.
Route of administration: Oral
Molecule: itraconazole